Dog Years

Company

Dog Years develops one asset, in veterinary (follistatin gene therapy in arthritis). Mostly gene therapy.

1
Asset
Furthest stage: Veterinary; 0
Trials: 0
Signals

Pipeline

1

follistatin gene therapy
Intramuscular plasmid delivery enables cells to produce and secrete follistatin, reducing inflammation and increasing muscle mass.
Veterinary, Gene therapy, arthritis, other degenerative conditions

Full company profiles: pipeline, trials, funding and people.

In the full profile

People6
Similar companies2